RhumbLine Advisers’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
RhumbLine Advisers's GLUE Position: Q3 2026 in Review
RhumbLine Advisers reduced its Monte Rosa Therapeutics (GLUE) stake by 2.3% in Q3 2026, selling an estimated $36.7K and leaving 92,450 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.
RhumbLine Advisers first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. The position peaked at $2.29M in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- RhumbLine Advisers held 92,450 shares of Monte Rosa Therapeutics worth $1.1M as of Q3 2026.
- RhumbLine Advisers sold 2,143 Monte Rosa Therapeutics shares in Q3 2026, an estimated $36.7K.
- Monte Rosa Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2210 holding.
- RhumbLine Advisers first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
- RhumbLine Advisers's Monte Rosa Therapeutics position peaked at $2.29M in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.